Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio di fase II per valutare NH102 per la depressione (NH102-21)

20 settembre 2026 aggiornato da: Jiangsu Nhwa Pharmaceutical Co., Ltd.

Uno studio clinico di fase II per esplorazione dose-esplica, una sperimentazione clinica di fase II per esplgolazione dose per valutare l'efficacia e la sicurezza di NH102 randomizzato, randomizzato, in doppio cieco, a doppio fitto

This study is a multicenter, randomized, double-blind, double-dummy, parallel-group, dose-finding Phase II clinical trial with placebo and active comparator duloxetine . It is designed to preliminarily assess the efficacy and safety of NH102 in patients with major depressive disorder and to provide the basis for the design of Phase III clinical trials.

Panoramica dello studio

Descrizione dettagliata

This trial consists of three periods: a screening period (up to 2 weeks), a double-blind treatment period (6 weeks), and a tapering-off period/safety follow-up (1 week). The screening period may last up to 14 days and a minimum of 1 day.

Baseline assessments will be conducted prior to randomization to confirm the eligibility of participants. A total of 240 patients with depression will be randomly assigned in a 1:1:1:1:1 ratio to three experimental drug groups (10 mg, 20 mg, and 30 mg), one active control group (duloxetine hydrochloride capsules 60 mg ), or one placebo group. The double-blind treatment period will last for 6 weeks, during which participants will take the assigned medications according to the specified dosing regimen and will be followed up at the end of weeks 1, 2, 4, and 6. After the treatment period, participants will enter a 1-week tapering-off period and will undergo safety follow-up at the end of week 7.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

243

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Anhui
      • Hefei, Anhui, Cina, 230000
        • Anhui Mental Health Center
    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina, 100096
        • Beijing Huilongguan Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Cina, 400036
        • Chongqing Mental Health Center
    • Fujian
      • Xiamen, Fujian, Cina, 361012
        • Xiamen Xianyue Hospital
    • Guangdong
      • Guangzhou, Guangdong, Cina, 510370
        • The Affiliated Brain Hospital of Guangzhou Medical University
      • Shenzhen, Guangdong, Cina, 518118
        • Shenzhen Kangning Hospital
    • Hebei
      • Baoding, Hebei, Cina, 071000
        • Hebei Mental Health Hospital
    • Henan
      • Xinxiang, Henan, Cina, 453000
        • The Second Affiliated Hospital of Henan Medical University
      • Zhumadian, Henan, Cina, 463000
        • Zhumadian Second People's Hospital
    • Hunan
      • Changsha, Hunan, Cina, 410007
        • Hunan Second people's Hospital
    • Jiangsu
      • Suzhou, Jiangsu, Cina, 215000
        • Suzhou Guangji Hospital
      • Wuxi, Jiangsu, Cina, 214000
        • Wuxi Mental Health Center
    • Jiangxi
      • Nanchang, Jiangxi, Cina, 330038
        • Nanchang Mental Health Center
    • Jilin
      • Siping, Jilin, Cina, 136000
        • Jilin Provincial Neuropsychiatric Hospital
    • Shandong
      • Jinan, Shandong, Cina, 250014
        • Shongdong Mental Health Center
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina, 200030
        • Shanghai Mental Health Center
    • Shanxi
      • Taiyuan, Shanxi, Cina, 030000
        • Frist Hospital of Shanxi Medical University
      • Xi’an, Shanxi, Cina, 710000
        • Xi'an Mental Health Center
    • Sichuan
      • Chengdu, Sichuan, Cina, 610072
        • Sichuan Provincial People's Hospital
      • Chengdu, Sichuan, Cina, 610000
        • The Fourth People's Hospital of Chengdu
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Cina, 300000
        • Tianjin Anding Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, Cina, 310003
        • Hangzhou Seventh People's Hospital
      • Huzhou, Zhejiang, Cina, 313000
        • Huzhou Third Municipal Hospital
      • Ningbo, Zhejiang, Cina, 315000
        • The Affiliated Kangning Hospital of Ningbo University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Male and female outpatients aged 18-65 years (inclusive).
  • Diagnosis of Major Depressive Disorder (MDD) according to DSM-5 criteria ( without psychotic features).
  • Hamilton Depression Rating Scale (HAM-D17) total score ≥ 22 at screening and baseline visits, with item 1 (depressed mood) score ≥ 2.
  • Clinical Global Impression-Severity (CGI-S) score ≥ 4 at screening and baseline.
  • Negative pregnancy test for women of childbearing potential.
  • Willingness to use effective contraception during the trial and for 3 months after the last dose.
  • Voluntary participation and signed informed consent.

Exclusion Criteria:

  • Duration of the current depressive episode in first-episode patients < 3 months.
  • Treatment-resistant depression (failure of ≥ 2 adequate antidepressant treatments).
  • Other psychiatric disorders (e.g., schizophrenia, bipolar disorder, anxiety disorders).
  • History of severe neurological diseases, epilepsy, or significant head trauma.
  • Unstable or severe cardiovascular, gastrointestinal, or endocrine diseases.
  • History of malignancy within the past 2 years.
  • History of increased intraocular pressure or untreated narrow-angle glaucoma.
  • Abnormal thyroid function not adequately controlled.
  • History of severe drug allergies or hypersensitivity to duloxetine or excipients.
  • Suicide attempt within the past year or significant suicide risk.
  • Substance abuse within the past year or positive at screening drug test.
  • Alcohol abuse (≥ 14 units/week) within the past year.
  • Previous treatment with duloxetine without adequate response.
  • Normative use of antidepressants within 2 weeks prior to screening.
  • Use of CYP2D6 or CYP1A2 potent inhibitors/inducers within 2 weeks prior to screening.
  • Participation in another clinical trial within the past 3 months.
  • Any condition deemed unsuitable by the investigator.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Placebo

Matched dosing regimen.Twice daily for 6 weeks, followed by a 1-week tapering period.

Sperimentale: NH102 10mg

5 mg twice daily over 6 weeks, followed by a 1-week tapering period.

10 mg twice daily over 6 weeks, followed by a 1-week tapering period.

15 mg twice daily over 6 weeks, followed by a 1-week tapering period.

Sperimentale: NH102 20mg

5 mg twice daily over 6 weeks, followed by a 1-week tapering period.

10 mg twice daily over 6 weeks, followed by a 1-week tapering period.

15 mg twice daily over 6 weeks, followed by a 1-week tapering period.

Sperimentale: NH102 30mg

5 mg twice daily over 6 weeks, followed by a 1-week tapering period.

10 mg twice daily over 6 weeks, followed by a 1-week tapering period.

15 mg twice daily over 6 weeks, followed by a 1-week tapering period.

Comparatore attivo: Duloxetina cloridrato enterico capsule

30 mg twice daily for 6 weeks, followed by a 1-week tapering period.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
17 items Hamilton Depression Scales (HAM-D17)
Lasso di tempo: 6 Weeks

Changes from baseline in the 17 items Hamilton Depression Scales (HAM-D17) total score at the end of treatment.

HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50. Higher scores indicate a worse outcome.

6 Weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
17 items Hamilton Depression Scales (HAM-D17)
Lasso di tempo: Week 2 and 4

Changes from baseline in the 17 items Hamilton Depression Scales (HAM-D17) total score at Week 2 and 4.

HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50. Higher scores indicate a worse outcome.

Week 2 and 4
Montgomery- Åsberg Depression Rating Scale(MADRS)
Lasso di tempo: 6 Weeks

Changes from baseline in the 10-items Montgomery- Åsberg Depression Scales (MADRS) total score at Week 2, Week 4 and the end of treatment.

MADRS is a standardized, clinician-administered rating scale that assesses 10 items characteristically associated with major depression. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

6 Weeks
Clinical Global Impression-Improvement (CGI-I)
Lasso di tempo: 6 Weeks

Changes from baseline in the CGI-I score at the end of treatment.

The Clinical Global Impression-Improvement (CGI-I) scale is a clinician-rated instrument designed to assess the overall improvement or worsening of a patient's condition relative to a baseline state. The following one query is rated on a seven-point scale: "Compared to the patient's condition at admission to the project, this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment."

6 Weeks
Clinical Global Impression-Severity (CGI-S)
Lasso di tempo: 6 Weeks

Changes from baseline in the Clinical Global Impression-Severity (CGI-S) score at the end of treatment.

The CGI-S asks the clinician one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.

6 Weeks
Hamilton Anxiety Rating Scale (HAM-A)
Lasso di tempo: 6 Weeks

Changes from baseline in the HAM-A total score at the end of treatment.

The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered assessment tool to measure the severity of anxiety symptoms. It consists of 14 items, each evaluating a specific symptom of anxiety, such as anxious mood, tension, fears, and somatic complaints. Each item is scored on a scale from 0 (None) to 4 ( Very severe. grossly disabling ), with the total score ranging from a minimum of 0 to a maximum of 56. Higher scores indicate greater severity of anxiety symptoms, reflecting a worse clinical outcome.

6 Weeks
Dimensional Anhedonia Rating Scale (DARS)
Lasso di tempo: 6 Weeks

Change from baseline in Dimensional Anhedonia Rating Scale (DARS) total score at the end of treatment.

The DARS is a self-report scale that measures anhedonia across the following 4 domains: hobbies/past-times, food/drinks, social activities, and sensory experiences. Within each domain, participants are required to provide at least two of their own examples of what they find rewarding. Subsequently, participants answer a set of standardized questions about desire, motivation, effort and consummatory pleasure for the examples provided. Responses were based on a 5-point Likert scale (Not at all=0; Slightly=1; Moderately=2; Mostly=3; Very Much=4), with the total score ranging from a minimum of 0 to a maximum of 68. A higher score reflects a better outcome.

6 Weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 dicembre 2024

Completamento primario (Effettivo)

30 luglio 2025

Completamento dello studio (Effettivo)

12 settembre 2025

Date di iscrizione allo studio

Primo inviato

16 febbraio 2025

Primo inviato che soddisfa i criteri di controllo qualità

19 febbraio 2025

Primo Inserito (Effettivo)

24 febbraio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

20 settembre 2026

Ultimo verificato

1 novembre 2025

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • NH102-21

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi